PMID- 17474141
OWN - NLM
STAT- MEDLINE
DCOM- 20071220
LR  - 20191210
IS  - 0269-3879 (Print)
IS  - 0269-3879 (Linking)
VI  - 21
IP  - 10
DP  - 2007 Oct
TI  - Sensitive determination of MDMA and its metabolite MDA in rat blood and brain 
      microdialysates by HPLC with fluorescence detection.
PG  - 1016-22
AB  - Simultaneous determination of 3,4-methylenedioxymethamphetamine (MDMA) and 
      3,4-methylenedioxyamphetamine (MDA) in rat blood and brain microdialysates by 
      high-performance liquid chromatography with fluorescence detection (HPLC-FL) was 
      developed. Microdialysates were directly subjected to derivatization with 
      4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl). The DIB-derivatives 
      of MDMA, MDA and the internal standard, 1-methyl-3-phenylpropylamine (MPPA), were 
      isocratically separated on an ODS column using a mixture of 50 mm phosphate 
      buffer (pH 7.0)-acetonitrile-methanol-2-propanol (50:45:5:2, v/v/v/v %) as an 
      eluent at a flow rate of 1.5 mL/min. The calibration curves of MDA and MDMA 
      spiked to blood and brain microdialysates were linear over the ranges 2.5-500 and 
      5.0-1000 ng/mL, respectively. The detection limits of MDA and MDMA were 1.2 and 
      4.2 for blood and 1.3 and 4.8 ng/mL for brain, respectively. Additionally, the 
      intra- and the inter-assay precisions were lower than 5.6% for the blood and 
      brain microdialysates (n = 4). The proposed method was successfully applied for 
      the monitoring of MDMA and its metabolite MDA in rat blood and brain 
      microdialysates, and the pharmacokinetic parameters of MDMA and MDA in the 
      microdialysates after administration of MDMA (5 mg/kg, i.p.) with or without 
      caffeine (20 mg/kg, i.p.) were evaluated.
CI  - 2007 John Wiley & Sons, Ltd
FAU - Tomita, Mamoru
AU  - Tomita M
AD  - Department of Clinical Pharmacy, Course of Pharmaceutical Sciences, Graduate 
      School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 
      852-8521, Japan.
FAU - Nakashima, Mihoko N
AU  - Nakashima MN
FAU - Wada, Mitsuhiro
AU  - Wada M
FAU - Nakashima, Kenichiro
AU  - Nakashima K
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Biomed Chromatogr
JT  - Biomedical chromatography : BMC
JID - 8610241
RN  - 0 (4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride)
RN  - 0 (Benzoates)
RN  - 0 (Fluorescent Dyes)
RN  - 0 (Imidazoles)
RN  - 4764-17-4 (3,4-Methylenedioxyamphetamine)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - 3,4-Methylenedioxyamphetamine/*analysis/chemistry/pharmacokinetics
MH  - Animals
MH  - Benzoates/chemistry
MH  - Blood Chemical Analysis
MH  - *Brain Chemistry
MH  - Calibration
MH  - Chromatography, High Pressure Liquid/instrumentation/methods
MH  - Fluorescent Dyes/*chemistry
MH  - Imidazoles/chemistry
MH  - Male
MH  - *Microdialysis/instrumentation/methods
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*analysis/chemistry/pharmacokinetics
MH  - Plasma/chemistry
MH  - Rats
MH  - Rats, Wistar
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
MH  - Substance Abuse Detection/instrumentation/methods
EDAT- 2007/05/03 09:00
MHDA- 2007/12/21 09:00
CRDT- 2007/05/03 09:00
PHST- 2007/05/03 09:00 [pubmed]
PHST- 2007/12/21 09:00 [medline]
PHST- 2007/05/03 09:00 [entrez]
AID - 10.1002/bmc.839 [doi]
PST - ppublish
SO  - Biomed Chromatogr. 2007 Oct;21(10):1016-22. doi: 10.1002/bmc.839.